Article cliniquePulmonary arterial hypertension (PAH) is a severe form of pulmonary hypertension that combines multiple alterations of pulmonary arteries, including, in particular, thrombotic and plexiform lesions. Multiple-pathological-insult animal models, developed to more closely mimic this human severe PAH form, often require complex and/or long experimental procedures while not displaying the entire panel of characteristic lesions observed in the human disease. In this study, we further characterized a rat model of severe PAH generated by combining a single injection of monocrotaline with 4 weeks exposure to chronic hypoxia. This model displays increased pulmonary arterial pressure, right heart altered function and remodeling, pulmona...
Pulmonary hypertension is called PH for short. It is caused by the pulmonary artery vascular disease...
Pulmonary arterial hypertension is a fatal disease associated with pulmonary vascular remodeling and...
In order to intervene appropriately and develop disease-modifying therapeutics for pulmonary arteria...
Pulmonary arterial hypertension (PAH) is a rare multifactorial disease characterized by abnormal hig...
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vasoproliferative disorder characte...
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vasoproliferative disorder characte...
Pulmonary arterial hypertension is a progressive syndrome based on diverse aetiologies, which is cha...
In spite of treatment, severe angioproliferative pulmonary arterial hypertension (PAH) remains a dis...
Rationale: The complex pathologies associated with severe pulmonary arterial hypertension (PAH) in m...
analogs, endothelin receptor antagonists, and phosphodiester-ase type 5 inhibitors in severe pulmona...
Pulmonary hypertension (PH) is an incurable condition inevitably resulting in death because of incre...
Pulmonary arterial hypertension (PAH) is a pulmonary angioproliferative disease with high morbidity ...
Pulmonary arterial hypertension (PAH) is a rare and fatal disease that affects the pulmonary artery ...
Pulmonary arterial hypertension (PAH) is a progressive lung vasculature disorder that results in ele...
Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease characterized by incre...
Pulmonary hypertension is called PH for short. It is caused by the pulmonary artery vascular disease...
Pulmonary arterial hypertension is a fatal disease associated with pulmonary vascular remodeling and...
In order to intervene appropriately and develop disease-modifying therapeutics for pulmonary arteria...
Pulmonary arterial hypertension (PAH) is a rare multifactorial disease characterized by abnormal hig...
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vasoproliferative disorder characte...
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vasoproliferative disorder characte...
Pulmonary arterial hypertension is a progressive syndrome based on diverse aetiologies, which is cha...
In spite of treatment, severe angioproliferative pulmonary arterial hypertension (PAH) remains a dis...
Rationale: The complex pathologies associated with severe pulmonary arterial hypertension (PAH) in m...
analogs, endothelin receptor antagonists, and phosphodiester-ase type 5 inhibitors in severe pulmona...
Pulmonary hypertension (PH) is an incurable condition inevitably resulting in death because of incre...
Pulmonary arterial hypertension (PAH) is a pulmonary angioproliferative disease with high morbidity ...
Pulmonary arterial hypertension (PAH) is a rare and fatal disease that affects the pulmonary artery ...
Pulmonary arterial hypertension (PAH) is a progressive lung vasculature disorder that results in ele...
Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease characterized by incre...
Pulmonary hypertension is called PH for short. It is caused by the pulmonary artery vascular disease...
Pulmonary arterial hypertension is a fatal disease associated with pulmonary vascular remodeling and...
In order to intervene appropriately and develop disease-modifying therapeutics for pulmonary arteria...